Velarion · Company Intelligence
Compensation Brief
Fiscal year 2023 · Filings through 2025-01-10

Poseida Therapeutics (PSTX)

CEO Mark Gergen was paid $3,818,018 in fiscal year 2023, ↓ down 12.6% from fiscal year 2022 (SEC filing 0000950170-24-048291 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,818,018 ↓
Mark Gergen total, FY2023
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
—
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Mark Gergen (Chief Executive Officer, President and Chairman), FY2023 total compensation $3,818,018 (base salary $611,667) [exec_comp, SEC accession 0000950170-24-048291, filed 2024-04-25]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

01

Summary Compensation Table — fiscal year 2023

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Mark Gergen$611,667$0$1,442,285$1,413,936$336,420$0$13,710$3,818,018
Chief Executive Officer, President and Chairman
Kristin Yarema380,6250934,910934,210171,280013,5402,434,565
President, Cell Therapy
Brent Warner445,7670496,330486,574200,600013,1811,642,452
President, Gene Therapy

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2023 totalFY2022 totalFY2021 totalΔ FY2022→2023
Mark Gergen$3,818,018$4,369,452—↓ −551,434
Kristin Yarema2,434,565———
Brent Warner1,642,4522,879,028—↓ −1,236,576

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Poseida Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper PSTX reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against PSTX
8 companies name PSTX as a compensation peer

Each company listed discloses PSTX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named PSTX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2023 total
Charles M. BaumIndependent Director$150,276
Cynthia CollinsIndependent Director$155,276
Eric OstertagFormer director (through FY2023)—
John P. SchmidLead Independent Director$175,109
Luke CorningIndependent Director$140,109
Marcea B. LloydIndependent Director$149,109
Rafael G. AmadoIndependent Director$248,172
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Mark J. GergenDirector2025-01-02D23,313$10$223,805CommonForm 4 ↗
John P. SchmidDirector2025-01-08D20,00000Derivative, Class A CommonForm 4 ↗
John P. SchmidDirector2025-01-08D16,03800Derivative, Class A CommonForm 4 ↗
John P. SchmidDirector2025-01-08D32,07600Derivative, Class A CommonForm 4 ↗
Mark J. GergenDirector2025-01-08D48,11500Derivative, Class A CommonForm 4 ↗
Harry J. LeonhardtGC & Chief Compliance Officer2025-01-08D137,00000Derivative, Class A CommonForm 4 ↗
Kristin YaremaPresident and CEO2025-01-08D345,20000Derivative, Class A CommonForm 4 ↗
Mark J. GergenDirector2025-01-08D518,50000Derivative, Class A CommonForm 4 ↗
Mark J. GergenDirector2025-01-08D636,726——CommonForm 4 ↗
Harry J. LeonhardtGC & Chief Compliance Officer2025-01-08D125,28300Derivative, Class A CommonForm 4 ↗
Harry J. LeonhardtGC & Chief Compliance Officer2025-01-08D72,56800Derivative, Class A CommonForm 4 ↗
Harry J. LeonhardtGC & Chief Compliance Officer2025-01-08D223,640——CommonForm 4 ↗
Syed Ali-aamir RizviChief Medical Officer2025-01-08D250,00000Derivative, Class A CommonForm 4 ↗
Johanna MyletChief Financial Officer2025-01-08D111,70000Derivative, Class A CommonForm 4 ↗
Johanna MyletChief Financial Officer2025-01-08D125,28300Derivative, Class A CommonForm 4 ↗
Johanna MyletChief Financial Officer2025-01-08D4,11700Derivative, Class A CommonForm 4 ↗
Charles M. BaumDirector2025-01-08D27,35000Derivative, Class A CommonForm 4 ↗
Cynthia CollinsDirector2025-01-08D87,44000Derivative, Class A CommonForm 4 ↗
Marcea B. LloydDirector2025-01-08D27,35000Derivative, Class A CommonForm 4 ↗
Marcea B. LloydDirector2025-01-08D20,00000Derivative, Class A CommonForm 4 ↗
Marcea B. LloydDirector2025-01-08D20,00000Derivative, Class A CommonForm 4 ↗
Marcea B. LloydDirector2025-01-08D32,07600Derivative, Class A CommonForm 4 ↗
Marcea B. LloydDirector2025-01-08D68,950——CommonForm 4 ↗
John P. SchmidDirector2025-01-08D20,00000Derivative, Class A CommonForm 4 ↗
John P. SchmidDirector2025-01-08D58,950——CommonForm 4 ↗
Luke CorningDirector2025-01-08D28,50000Derivative, Class A CommonForm 4 ↗
Luke CorningDirector2025-01-08D45,83300Derivative, Class A CommonForm 4 ↗
Luke CorningDirector2025-01-08D58,950——CommonForm 4 ↗
Rafael G. AmadoDirector2025-01-08D58,950——CommonForm 4 ↗
Mark J. GergenDirector2025-01-08D172,60000Derivative, Class A CommonForm 4 ↗
Rafael G. AmadoDirector2025-01-08D27,35000Derivative, Class A CommonForm 4 ↗
Cynthia CollinsDirector2025-01-08D27,35000Derivative, Class A CommonForm 4 ↗
Cynthia CollinsDirector2025-01-08D28,50000Derivative, Class A CommonForm 4 ↗
Mark J. GergenDirector2025-01-08D364,06000Derivative, Class A CommonForm 4 ↗
Mark J. GergenDirector2025-01-08D75,00000Derivative, Class A CommonForm 4 ↗
Mark J. GergenDirector2025-01-08D240,72100Derivative, Class A CommonForm 4 ↗
John P. SchmidDirector2025-01-08D25,83300Derivative, Class A CommonForm 4 ↗
Luke CorningDirector2025-01-08D27,35000Derivative, Class A CommonForm 4 ↗
Kristin YaremaPresident and CEO2025-01-08D498,32500Derivative, Class A CommonForm 4 ↗
Charles M. BaumDirector2025-01-08D27,35000Derivative, Class A CommonForm 4 ↗
Charles M. BaumDirector2025-01-08D78,600——CommonForm 4 ↗
Kristin YaremaPresident and CEO2025-01-08D615,836——CommonForm 4 ↗
Luke CorningDirector2025-01-08D27,35000Derivative, Class A CommonForm 4 ↗
Mark J. GergenDirector2025-01-08D342,00000Derivative, Class A CommonForm 4 ↗
Harry J. LeonhardtGC & Chief Compliance Officer2025-01-08D111,70000Derivative, Class A CommonForm 4 ↗
Harry J. LeonhardtGC & Chief Compliance Officer2025-01-08D160,38500Derivative, Class A CommonForm 4 ↗
Syed Ali-aamir RizviChief Medical Officer2025-01-08D185,000——CommonForm 4 ↗
Johanna MyletChief Financial Officer2025-01-08D72,56800Derivative, Class A CommonForm 4 ↗
Johanna MyletChief Financial Officer2025-01-08D65,00000Derivative, Class A CommonForm 4 ↗
Johanna MyletChief Financial Officer2025-01-08D82,00000Derivative, Class A CommonForm 4 ↗
Johanna MyletChief Financial Officer2025-01-08D35,00000Derivative, Class A CommonForm 4 ↗
Johanna MyletChief Financial Officer2025-01-08D254,852——CommonForm 4 ↗
Charles M. BaumDirector2025-01-08D57,00000Derivative, Class A CommonForm 4 ↗
Cynthia CollinsDirector2025-01-08D27,35000Derivative, Class A CommonForm 4 ↗
Cynthia CollinsDirector2025-01-08D58,950——CommonForm 4 ↗
Marcea B. LloydDirector2025-01-08D27,35000Derivative, Class A CommonForm 4 ↗
Marcea B. LloydDirector2025-01-08D28,50000Derivative, Class A CommonForm 4 ↗
Marcea B. LloydDirector2025-01-08D25,83300Derivative, Class A CommonForm 4 ↗
Marcea B. LloydDirector2025-01-08D16,03800Derivative, Class A CommonForm 4 ↗
John P. SchmidDirector2025-01-08D27,35000Derivative, Class A CommonForm 4 ↗
John P. SchmidDirector2025-01-08D27,35000Derivative, Class A CommonForm 4 ↗
John P. SchmidDirector2025-01-08D28,50000Derivative, Class A CommonForm 4 ↗
Rafael G. AmadoDirector2025-01-08D55,20000Derivative, Class A CommonForm 4 ↗
Malin Life Sciences Holdings LtdGreater-than-10% holder2025-01-08D11,835,673——CommonForm 4 ↗
Johanna MyletChief Financial Officer2025-01-08D80,19200Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

04

Outstanding equity awards at fiscal year-end 2023

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Mark GergenRSU269,586—$1,442,285
Mark GergenRSU267,900—1,272,525
Mark GergenOption99,7509.15—
Brent WarnerOption101,7935.35—
Kristin YaremaRSU356,836—934,910
Brent WarnerRSU230,910—789,712
Mark GergenOption10,93816—
Brent WarnerRSU92,772—496,330
Mark GergenOption295,8005.35—
Mark GergenOption280,8554.75—
Kristin YaremaOption415,2722.62—
Brent WarnerOption242,4573.42—
05

Incentive-plan design — the Compensation Discussion & Analysis

The Company's compensation program is designed to provide appropriate incentives to executives to achieve defined annual performance goals and to reward them for achievement towards these goals. Long-term incentives are provided through equity awards, historically stock options and more recently RSUs, to align executive interests with stockholders.

CEO STI target (% of salary)55%
CEO LTI target (% of salary)—
Independent consultantAon Consulting, Inc.
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20242024-06-17—————
20232023-06-15—————
20222022-06-16—————
20212021-06-16—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20242024-06-17—a
20232023-06-15—b
20222022-06-16—c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2023

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Rafael G. AmadoIndependent · Compensation Committee · Science and Technology Committee (4) (Chair)$31,667$108,468$108,037—$0$248,172
John P. SchmidIndependent · Audit Committee (Chair) · Nominating and Corporate Governance Committee79,00048,53647,573—0175,109
Cynthia CollinsIndependent · Audit Committee · Compensation Committee (Chair) · Science and Technology Committee (4)59,16748,53647,573—0155,276
Charles M. BaumIndependent · Audit · Compensation · Science and Technology Committee54,16748,53647,573—0150,276
Marcea B. LloydIndependent · Compensation · Nominating and Corporate Governance (Chair)53,00048,53647,573—0149,109
Luke CorningIndependent · Nominating and Corporate Governance Committee44,00048,53647,573—0140,109
Eric OstertagNot independent · Departed during FY000—00
Mark J. GergenEmployee director · Board Chair000—00
Kristin YaremaEmployee director · Newly elected000—00
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$275,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)15,000 / 10,000 / 8,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2023
Cash retainers and fees$321,001
Equity awards (grant-date value)$351,148
All other compensation$0
Total cost of the board$672,149

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Poseida Therapeutics2023Mark Gergen$611,667$1,442,285$1,413,936$336,420$3,818,018

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Poseida Therapeutics in fiscal 2023?
As disclosed, Mark Gergen (Chief Executive Officer, President and Chairman) was the highest-paid executive at Poseida Therapeutics in fiscal 2023, with total compensation of $3,818,018.
How much does Poseida Therapeutics spend in total on board compensation for fiscal 2023?
As disclosed, Poseida Therapeutics reported total board compensation of $672,149 for fiscal 2023.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Mark GergenDEF 14A2024-04-250000950170-24-048291Section “Executive Compensation”. As printed: 3,818,018. Filing ↗machine: span 428155–428164
2Section 01, Kristin YaremaDEF 14A2024-04-250000950170-24-048291Section “Executive Compensation”. As printed: 2,434,565. Filing ↗machine: r4 · c25 · span 441659–441668
3Section 01, Brent WarnerDEF 14A2024-04-250000950170-24-048291Section “Executive Compensation”. As printed: 1,642,452. Filing ↗machine: r6 · c25 · span 453155–453164
4Section 08, Rafael G. AmadoDEF 14A2024-04-250000950170-24-048291Section “Director Compensation”. As printed: 248,172. Filing ↗machine: span 654831–655022
5Section 08, John P. SchmidDEF 14A2024-04-250000950170-24-048291Section “Director Compensation”. As printed: 175,109. Filing ↗machine: span 675917–676108
6Section 08, Cynthia CollinsDEF 14A2024-04-250000950170-24-048291Section “Director Compensation”. As printed: 155,276. Filing ↗machine: span 663244–663435
7Section 08, Charles M. BaumDEF 14A2024-04-250000950170-24-048291Section “Director Compensation”. As printed: 150,276. Filing ↗machine: t17 · r3 · c15 · span 659044–659235
8Section 08, Marcea B. LloydDEF 14A2024-04-250000950170-24-048291Section “Director Compensation”. As printed: 149,109. Filing ↗machine: t17 · r6 · c15 · span 671704–671895
9Section 08, Luke CorningDEF 14A2024-04-250000950170-24-048291Section “Director Compensation”. As printed: 140,109. Filing ↗machine: span 667441–667632
10Section 08, Eric OstertagDEF 14A2024-04-250000950170-24-048291Section “Director Compensation”. As printed: 0. Filing ↗
11Section 08, Mark J. GergenDEF 14A2024-04-250000950170-24-048291Section “Director Compensation”. As printed: 0. Filing ↗
12Section 08, Kristin YaremaDEF 14A2024-04-250000950170-24-048291Section “Director Compensation”. As printed: 0. Filing ↗
13Section 02, Mark J. Gergen 2025-01-02Form 42025-01-030000950170-25-001527Insider equity transaction reported since the proxy statement. Filing ↗
14Section 02, John P. Schmid 2025-01-08Form 42025-01-080001415889-25-001088Insider equity transaction reported since the proxy statement. Filing ↗
15Section 02, John P. Schmid 2025-01-08Form 42025-01-080001415889-25-001088Insider equity transaction reported since the proxy statement. Filing ↗
16Section 02, John P. Schmid 2025-01-08Form 42025-01-080001415889-25-001088Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Mark J. Gergen 2025-01-08Form 42025-01-080001415889-25-001081Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Harry J. Leonhardt 2025-01-08Form 42025-01-080001415889-25-001082Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Kristin Yarema 2025-01-08Form 42025-01-080001415889-25-001080Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Mark J. Gergen 2025-01-08Form 42025-01-080001415889-25-001081Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Mark J. Gergen 2025-01-08Form 42025-01-080001415889-25-001081Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Harry J. Leonhardt 2025-01-08Form 42025-01-080001415889-25-001082Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Harry J. Leonhardt 2025-01-08Form 42025-01-080001415889-25-001082Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Harry J. Leonhardt 2025-01-08Form 42025-01-080001415889-25-001082Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Syed Ali-aamir Rizvi 2025-01-08Form 42025-01-080001415889-25-001083Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Johanna Mylet 2025-01-08Form 42025-01-080001415889-25-001084Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Johanna Mylet 2025-01-08Form 42025-01-080001415889-25-001084Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Johanna Mylet 2025-01-08Form 42025-01-080001415889-25-001084Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Charles M. Baum 2025-01-08Form 42025-01-080001415889-25-001085Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Cynthia Collins 2025-01-08Form 42025-01-080001415889-25-001086Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Marcea B. Lloyd 2025-01-08Form 42025-01-080001415889-25-001087Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Marcea B. Lloyd 2025-01-08Form 42025-01-080001415889-25-001087Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Marcea B. Lloyd 2025-01-08Form 42025-01-080001415889-25-001087Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Marcea B. Lloyd 2025-01-08Form 42025-01-080001415889-25-001087Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Marcea B. Lloyd 2025-01-08Form 42025-01-080001415889-25-001087Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, John P. Schmid 2025-01-08Form 42025-01-080001415889-25-001088Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, John P. Schmid 2025-01-08Form 42025-01-080001415889-25-001088Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Luke Corning 2025-01-08Form 42025-01-080001415889-25-001089Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Luke Corning 2025-01-08Form 42025-01-080001415889-25-001089Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Luke Corning 2025-01-08Form 42025-01-080001415889-25-001089Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Rafael G. Amado 2025-01-08Form 42025-01-080001415889-25-001090Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Mark J. Gergen 2025-01-08Form 42025-01-080001415889-25-001081Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Rafael G. Amado 2025-01-08Form 42025-01-080001415889-25-001090Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Cynthia Collins 2025-01-08Form 42025-01-080001415889-25-001086Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Cynthia Collins 2025-01-08Form 42025-01-080001415889-25-001086Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Mark J. Gergen 2025-01-08Form 42025-01-080001415889-25-001081Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Mark J. Gergen 2025-01-08Form 42025-01-080001415889-25-001081Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Mark J. Gergen 2025-01-08Form 42025-01-080001415889-25-001081Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, John P. Schmid 2025-01-08Form 42025-01-080001415889-25-001088Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Luke Corning 2025-01-08Form 42025-01-080001415889-25-001089Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Kristin Yarema 2025-01-08Form 42025-01-080001415889-25-001080Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Charles M. Baum 2025-01-08Form 42025-01-080001415889-25-001085Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Charles M. Baum 2025-01-08Form 42025-01-080001415889-25-001085Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Kristin Yarema 2025-01-08Form 42025-01-080001415889-25-001080Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Luke Corning 2025-01-08Form 42025-01-080001415889-25-001089Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Mark J. Gergen 2025-01-08Form 42025-01-080001415889-25-001081Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Harry J. Leonhardt 2025-01-08Form 42025-01-080001415889-25-001082Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Harry J. Leonhardt 2025-01-08Form 42025-01-080001415889-25-001082Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Syed Ali-aamir Rizvi 2025-01-08Form 42025-01-080001415889-25-001083Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Johanna Mylet 2025-01-08Form 42025-01-080001415889-25-001084Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Johanna Mylet 2025-01-08Form 42025-01-080001415889-25-001084Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Johanna Mylet 2025-01-08Form 42025-01-080001415889-25-001084Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Johanna Mylet 2025-01-08Form 42025-01-080001415889-25-001084Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Johanna Mylet 2025-01-08Form 42025-01-080001415889-25-001084Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Charles M. Baum 2025-01-08Form 42025-01-080001415889-25-001085Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Cynthia Collins 2025-01-08Form 42025-01-080001415889-25-001086Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Cynthia Collins 2025-01-08Form 42025-01-080001415889-25-001086Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Marcea B. Lloyd 2025-01-08Form 42025-01-080001415889-25-001087Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Marcea B. Lloyd 2025-01-08Form 42025-01-080001415889-25-001087Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Marcea B. Lloyd 2025-01-08Form 42025-01-080001415889-25-001087Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Marcea B. Lloyd 2025-01-08Form 42025-01-080001415889-25-001087Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, John P. Schmid 2025-01-08Form 42025-01-080001415889-25-001088Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, John P. Schmid 2025-01-08Form 42025-01-080001415889-25-001088Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, John P. Schmid 2025-01-08Form 42025-01-080001415889-25-001088Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Rafael G. Amado 2025-01-08Form 42025-01-080001415889-25-001090Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Malin Life Sciences Holdings Ltd 2025-01-08Form 42025-01-100001104659-25-002540Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Johanna Mylet 2025-01-08Form 42025-01-080001415889-25-001084Insider equity transaction reported since the proxy statement. Filing ↗
78Section 06, 2024 voteForm 8-K2024-06-180000950170-24-074860Item 5.07 · say-on-pay result. As reported: —. Filing ↗
79Section 06, 2023 voteForm 8-K2023-06-160000950170-23-028588Item 5.07 · say-on-pay result. As reported: —. Filing ↗
80Section 06, 2022 voteForm 8-K2022-06-160001564590-22-023456Item 5.07 · say-on-pay result. As reported: —. Filing ↗
81Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
82Section 09b board cost (computed)Computed——Cash 321,001 + equity 351,148 + all other 0 = 672,149, summed across the director compensation table rows.machine: formula: Σ = 672,149
83Poseida Therapeutics (subject), Section 10b CEO totalDEF 14A2024-04-250000950170-24-048291CEO total compensation as printed in Poseida Therapeutics's own proxy. As printed: 3,818,018. Filing ↗machine: span 428155–428164

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.